Muscle ultrasonography: a potential new tool to diagnose and evaluate treatment in dermatomyositis and polymyositis

Muscle ultrasonography: a potential new tool to diagnose and evaluate treatment in dermatomyositis and polymyositis - Muscle ultrasonography in dermatomyositis & polymyositis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34515

Enrollment

154

Registered

2011-02-24

Start date

2011-03-07

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myositis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic value muscle ultrasound: patients suspected for the diagnosis inflammatory myopathies. 2. Monitoring disease activity: Patients diagnosed with dermatomyositis and polymyositis according to the Bohan & Peter criteria 3. Corticosteroïd myopathy: Patients suspected for the diagnose of a corticosteroïd myopathy

Exclusion criteria

Exclusion criteria: Patients suffering from other neuromuscular diseases.

Design outcomes

Primary

Measure	Time frame
1. Diagnostic value muscle ultrasound: Sensitivity, specificity en predictive value 2. Monitoring disease activitiy muscle ultrasound: Correlation between muscle ultrasound and muscle strength/function (MRC and dynamometry), patient reported outcome (HAQ, SF-36, VAS patient and patient reported outcome questionnaire), Myositis Disease Activity Assessment Tool (MDAAT) and Myositis Damage index (MDI). 3. Corticosteroid myopathy: Structural muscle muscle changes defined by ultasound in patients with chronic corticosteroid use.	—

Measure

Time frame

1. Diagnostic value muscle ultrasound: Sensitivity, specificity en predictive value 2. Monitoring disease activitiy muscle ultrasound: Correlation between muscle ultrasound and muscle strength/function (MRC and dynamometry), patient reported outcome (HAQ, SF-36, VAS patient and patient reported outcome questionnaire), Myositis Disease Activity Assessment Tool (MDAAT) and Myositis Damage index (MDI). 3. Corticosteroid myopathy: Structural muscle muscle changes defined by ultasound in patients with chronic corticosteroid use.

—

Countries

Netherlands

Outcome results